580
Participants
Start Date
September 30, 2004
Study Completion Date
December 31, 2006
Tesaglitazar
Glibenclamide
Research Site, Antwerp
Research Site, Braine-l'Alleud
Research Site, Hasselt
Research Site, Liège
Research Site, Merksem
Research Site, Sint-Gillis-Waas
Research Site, Steenokkerzeel
Research Site, Shatin, N.T.
Research Site, Balatonfüred
Research Site, Budapest
Research Site, Kaposvár
Research Site, Kecskemét
Research Site, Székesfehérvár
Research Site, Arenzano
Research Site, Chiavari (GE)
Research Site, Chieri
Research Site, Gubbio (PG)
Research Site, Milan
Research Site, Napoli
Research Site, Padua
Research Site, Perugia
Research Site, Piacenza
Research Site, Reggio Calabria
Research Site, Reggio Emilia
Research Site, Rho
Research Site, Roma
Research Site, Udine
Research Site, Kubang Kerian
Research Site, Kuala Lampur
Research Site, México
Research Site, Guadalajara
Research Site, Zapopan
Research Site, Veracruz
Research Site, Ås
Research Site, Bergen
Research Site, Kongsvinger
Research Site, Lysaker
Research Site, Oslo
Research Site, Skedsmokorset
Research Site, Sørumstand
Research Site, Trondheim
Research Site, Manila
Research Site, Pasig
Research Site, Krakow
Research Site, Lublin
Research Site, P³ock
Research Site, Toruñ
Research Site, Tychy
Research Site, Warsaw
Research Site, £ód?
Research Site, Bratislava
Research Site, Ilava
Research Site, Košice
Research Site, Kysucké Nové Mesto
Research Site, Lučenec
Research Site, Ľubochňa
Research Site, Nitra
Research Site, Prešov
Research Site, Trnava
Research Site, Cape Town
Research Site, Durban
Research Site, Houghton Gauteng
Research Site, Changhua
Research Site, Taichung
Research Site, Taipei
Research Site, Bangkok
Lead Sponsor
AstraZeneca
INDUSTRY